UnipharDUB:UPR +2.69%79 3-Year RORE % is 5.76 as of Dec. 2025. GuruFocus rates DUB:UPR with a GF Score™ of 79/100 and a GF Value™ of €3.64 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 111 Medical Distribution companies, Uniphar ranks worse than 58.56% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Uniphar's 3-Year RORE % for the quarter that ended in Dec. 2025 was 5.76%.
The industry rank for Uniphar's 3-Year RORE % or its related term are showing as below:
DUB:UPR's 3-Year RORE % is ranked worse than 58.56% of 111
companies
in the Medical Distribution industry
Industry Median: 14.45
vs DUB:UPR: 5.76
Uniphar (DUB:UPR) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Uniphar 3-Year RORE % Related Terms
Uniphar 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Uniphar's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DUB:UPR vs MCK, CAH, COR: 3-Year RORE % Comparison
For the Medical Distribution subindustry, Uniphar's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar 3-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Uniphar's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Uniphar (DUB:UPR) has a 3-Year RORE % of 5.76 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Uniphar and its competitors. According to the industry distribution chart, Uniphar ranks #65 out of 111 companies in the Medical Distribution industry, placing it in the top 58.6%.
Is Uniphar's 3-Year RORE % too high?
Uniphar's current 3-Year RORE % is 5.76. The Medical Distribution industry median 3-Year RORE % is 14.45. Uniphar's value of 5.76 is 60.1% below this industry median. Based on the distribution chart, Uniphar ranks #65 out of 111 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Uniphar has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's 3-Year RORE % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Uniphar ranks #65 out of 111 companies for 3-Year RORE %. This places Uniphar in the lower half of its industry. The industry median 3-Year RORE % is 14.45. Uniphar's value of 5.76 is 60.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Distribution company?
The median 3-Year RORE % among Medical Distribution companies is 14.45, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current 3-Year RORE % of 5.76 is 60.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Uniphar and its competitors. For the Medical Distribution industry, the median 3-Year RORE % is 14.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current 3-Year RORE % is 5.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €4.78 — trading 31.3% above its estimated fair value. The current 3-Year RORE % is 5.76 and 60.1% below the Medical Distribution industry median of 14.45. Uniphar's overall GF Score™ is 79/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current 3-Year RORE % is 5.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (DUB:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of €4.78 is trading 31.3% above its estimated GF Value™ of €3.64.
GuruFocus considers Uniphar to be Significantly Overvalued.
Key valuation signals for DUB:UPR:
3-Year RORE %: 5.76
GF Value™: €3.64 vs. price of €4.78 (31.3% above fair value)
Industry Position: 60.1% below the Medical Distribution median (#65 of 111)
No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
79GF Score
Get the complete analysis for DUB:UPR
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DUB:UPR has been successfully added to your 
